Fouad Namouni

Fouad Namouni (chief executive) discloses dealings in 2 companies, chiefly Blueprint Medicines Corp and Aprea Therapeutics, Inc. Between 30 June 2021 and 17 July 2025, the trades on record add up to 14 filings.

On the market, this insider has only sold: 8 sales, €2.0M in total. Other entries cover 6 share grants. In 2025 alone, the filings show no purchases and 1 sale.

Most recently, on 21 July 2025, the filings show a share grant in Blueprint Medicines Corp. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.